Walleye Trading
NKTR icon

Walleye Trading’s Nektar Therapeutics NKTR Stock Holding History

Walleye Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,787
Closed -$144K – 5498
2022
Q1 		$144K Buy
1,787
+1,107
+163% +$164K ﹤0.01% 4038
2021
Q4 		$138K Sell
680
-980
-59% -$213K ﹤0.01% 4190
2021
Q3 		$447K Buy
+1,660
New +$399K ﹤0.01% 3025
2021
Q1 		– Sell
-1,153
Closed -$294K – 5133
2020
Q4 		$294K Buy
+1,153
New +$298K ﹤0.01% 3157
2020
Q3 		– Sell
-253
Closed -$88K – 4447
2020
Q2 		$88K Sell
253
-2,614
-91% -$816K ﹤0.01% 3576
2020
Q1 		$768K Buy
2,867
+1,287
+81% +$398K 0.01% 1505
2019
Q4 		$512K Sell
1,580
-1,780
-53% -$516K ﹤0.01% 2394
2019
Q3 		$918K Buy
3,360
+3,180
+1,767% +$1.17M 0.01% 1661
2019
Q2 		$96K Sell
180
-113
-39% -$56.7K ﹤0.01% 3325
2019
Q1 		$148K Buy
293
+260
+788% +$154K ﹤0.01% 3242
2018
Q4 		$16K Sell
33
-1,394
-98% -$841K ﹤0.01% 4380
2018
Q3 		$1.3M Buy
1,427
+1,014
+246% +$865K 0.01% 1792
2018
Q2 		$303K Sell
413
-567
-58% -$654K ﹤0.01% 3284
2018
Q1 		$1.56M Buy
980
+773
+373% +$996K 0.01% 1469
2017
Q4 		$186 Sell
207
-20
-9% -$11.8K ﹤0.01% 3499
2017
Q3 		$82 Sell
227
-360
-61% -$113K ﹤0.01% 3675
2017
Q2 		$172 Buy
587
+60
+11% +$17.3K ﹤0.01% 3222
2017
Q1 		$185 Buy
527
+460
+687% +$103K ﹤0.01% 2999
2016
Q4 		$12K Sell
67
-213
-76% -$43.3K ﹤0.01% 4258
2016
Q3 		$72K Sell
280
-33
-11% -$8.5K ﹤0.01% 3533
2016
Q2 		$67K Buy
313
+40
+15% +$8.94K ﹤0.01% 3792
2016
Q1 		$57K Sell
273
-207
-43% -$39.8K ﹤0.01% 3774
2015
Q4 		$121K Buy
480
+460
+2,300% +$94.6K ﹤0.01% 3138
2015
Q3 		$3K Sell
20
-60
-75% -$10.6K ﹤0.01% 4718
2015
Q2 		$16K Buy
80
+7
+10% +$1.21K ﹤0.01% 4097
2015
Q1 		$12K Buy
+73
New +$15K ﹤0.01% 3669
2014
Q4 		– Sell
-200
Closed -$36K – 4418
2014
Q3 		$36K Sell
200
-427
-68% -$81.7K ﹤0.01% 3313
2014
Q2 		$120 Buy
627
+440
+235% +$77.8K ﹤0.01% 2345
2014
Q1 		$34 Buy
+187
New +$37K ﹤0.01% 2885

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Walleye Trading's NKTR Position: Q2 2023 in Review

Walleye Trading sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 5,538 shares — an estimated $58.4K sold.

Walleye Trading first reported a position in NKTR in Q2 2014 and held it in 24 quarters. The position peaked at $681K in Q3 2021. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • Walleye Trading reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Trading sold 5,538 Nektar Therapeutics shares in Q2 2023, an estimated $58.4K.
  • Walleye Trading first reported a position in Nektar Therapeutics in Q2 2014 and held it in 24 quarters.
  • Walleye Trading's Nektar Therapeutics position peaked at $681K in Q3 2021.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.